Common Hospital Ingredient Perfusate Equivalent to Standard Krebs–Henseleit Buffer with Serum Albumin Derived Perfusate in Negative Pressure Ventilation Ex Vivo Lung Perfusion

    loading  Checking for direct PDF access through Ovid


IntroductionNormothermic ex-vivo lung perfusion (EVLP) using negative pressure ventilation (NPV) and red blood cell-based perfusate solutions have been shown to decrease edema formation and pro-inflammatory cytokine production compared to positive pressure ventilation (PPV). We sought to develop a common hospital ingredient derived perfusate (CHIP) with equivalent functional and inflammatory characteristics to the standard Krebs–Henseleit buffer with 8% serum albumin derived perfusate (KHB-Alb) in order to improve access and reduce costs of ex vivo organ perfusion.MethodsPorcine lungs were perfused using NPV-EVLP for 12 hours in a normothermic state, and were allocated to two groups: KHB-Alb (n=8) vs CHIP (n=4). Physiologic parameters, cytokine profiles, and edema formation were compared between treatment groups.ResultsPerfused lungs in both groups demonstrated equivalent oxygenation (partial pressure of arterial oxygen/ fraction of inspired oxygen ratio >350 mmHg) and physiologic parameters. There was equivalent generation of tumor necrosis factor-α, irrespective of perfusate solution used, when comparing CHIP vs KHB-Alb. Pig lungs developed equivalent edema formation between groups (CHIP: 15.7 ± 5.8%, STEEN 19.5 ± 4.4%, p>0.05).ConclusionA perfusate derived of common hospital ingredients provides equivalent results to standard Krebs–Henseleit buffer with 8% serum albumin based perfusate in NPV-EVLP.Canadian Institutes for Health Research - Canadian National Transplant Research Program (CIHR-CNTRP). University Hospital Foundation (UHF). Mazankowski Alberta Heart Institute - University Hospital Foundation Gerald Averback Award in Cardiovascular Gene Therapy / Genomics and Vascular Biology.

    loading  Loading Related Articles